

Ivan Bieche

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3559177/publications.pdf>

Version: 2024-02-01

369
papers

19,164
citations

10389

72
h-index

20961

115
g-index

376
all docs

376
docs citations

376
times ranked

31187
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. <i>Journal of Clinical Pathology</i> , 2023, 76, 126-132.	2.0	7
2	Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy. <i>Biomedicines</i> , 2022, 10, 240.	3.2	1
3	Value of the loss of heterozygosity to BRCA1 variant classification. <i>Npj Breast Cancer</i> , 2022, 8, 9.	5.2	2
4	Prognostic Value of <i>Fusobacterium nucleatum</i> after Abdominoperineal Resection for Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1606.	3.7	7
5	Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft. <i>Cancers</i> , 2022, 14, 1486.	3.7	10
6	Upregulated flotillins and sphingosine kinase 2 derail AXL vesicular traffic to promote epithelial-mesenchymal transition. <i>Journal of Cell Science</i> , 2022, 135, .	2.0	6
7	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
8	Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma. <i>Molecular Oncology</i> , 2022, 16, 3001-3016.	4.6	7
9	Kindlin-1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types. <i>Clinical and Translational Medicine</i> , 2022, 12, e813.	4.0	0
10	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	11
11	Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIRO2-Lung/IFCT 1301 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4018-4026.	7.0	4
12	PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101553.	1.5	11
13	Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial. <i>Molecular Oncology</i> , 2021, 15, 104-115.	4.6	10
14	Interleukin-8 Receptors CXCR1 and CXCR2 Are Not Expressed by Endothelial Colony-forming Cells. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 628-638.	3.8	0
15	Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site. <i>British Journal of Cancer</i> , 2021, 124, 777-785.	6.4	44
16	Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). <i>JCO Precision Oncology</i> , 2021, 5, 215-226.	3.0	22
17	Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1405-1436.	4.5	21
18	Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus-Associated Gastric Adenocarcinoma With ERBB2 Amplification. <i>JCO Precision Oncology</i> , 2021, 5, 370-377.	3.0	2

#	ARTICLE	IF	CITATIONS
19	Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. <i>Genome Medicine</i> , 2021, 13, 44.	8.2	13
20	Prognostic value of intratumoral <i>Fusobacterium nucleatum</i> and association with immune-related gene expression in oral squamous cell carcinoma patients. <i>Scientific Reports</i> , 2021, 11, 7870.	3.3	31
21	High <i>in vitro</i> and <i>in vivo</i> synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC. <i>Oncotarget</i> , 2021, 12, 859-872.	1.8	4
22	Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance. <i>Oncogene</i> , 2021, 40, 4019-4032.	5.9	19
23	Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. <i>Breast Cancer Research</i> , 2021, 23, 57.	5.0	7
24	5â€² Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints. <i>Cancers</i> , 2021, 13, 3171.	3.7	5
25	Definition of Biologically Distinct Groups of Conjunctival Melanomas According to Etiological Factors and Implications for Precision Medicine. <i>Cancers</i> , 2021, 13, 3836.	3.7	10
26	Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5869-5877.	7.0	36
27	Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2021, 39, 1641-1648.	2.6	9
28	Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials. <i>Translational Oncology</i> , 2021, 14, 101133.	3.7	6
29	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. <i>Journal of Hematology and Oncology</i> , 2021, 14, 143.	17.0	7
30	The mitochondrially-localized nucleoside diphosphate kinase D (NME4) is a novel metastasis suppressor. <i>BMC Biology</i> , 2021, 19, 228.	3.8	21
31	Biopathological Significance of PIWIâ€”piRNA Pathway Deregulation in Invasive Breast Carcinomas. <i>Cancers</i> , 2020, 12, 2833.	3.7	6
32	Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer. <i>Cancers</i> , 2020, 12, 2882.	3.7	13
33	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2020, 10, 16641.	3.3	10
34	PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. <i>Nature Communications</i> , 2020, 11, 4053.	12.8	77
35	Human Aortic Valve Interstitial Cells Display Proangiogenic Properties During Calcific Aortic Valve Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 41, 415-429.	2.4	12
36	Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas. <i>Analytical Cellular Pathology</i> , 2020, 2020, 1-10.	1.4	3

#	ARTICLE	IF	CITATIONS
37	EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma. <i>Scientific Reports</i> , 2020, 10, 7998.	3.3	5
38	MMP2 as an independent prognostic stratifier in oral cavity cancers. <i>Oncolmmunology</i> , 2020, 9, 1754094.	4.6	15
39	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	86
40	A single droplet digital PCR for ESR1 activating mutations detection in plasma. <i>Oncogene</i> , 2020, 39, 2987-2995.	5.9	42
41	Tubulin polyglutamylation is a general traffic control mechanism in hippocampal neurons. <i>Journal of Cell Science</i> , 2020, 133, .	2.0	39
42	ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. <i>Nucleic Acids Research</i> , 2020, 48, 2676-2693.	14.5	30
43	The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis. <i>Scientific Reports</i> , 2020, 10, 6920.	3.3	5
44	ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. <i>Bioinformatics</i> , 2020, 36, 3888-3889.	4.1	35
45	Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2020, 17, 208-217.	3.0	23
46	Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. <i>Theranostics</i> , 2020, 10, 1531-1543.	10.0	34
47	Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. <i>Oncology Letters</i> , 2019, 18, 674-686.	1.8	18
48	P-cadherin-induced decorin secretion is required for collagen fiber alignment and directional collective cell migration. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	14
49	Immune gene expression in head and neck squamous cell carcinoma patients. <i>European Journal of Cancer</i> , 2019, 121, 210-223.	2.8	45
50	Loss of the deglutamylase CCP5 perturbs multiple steps of spermatogenesis and leads to male infertility. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	25
51	Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz055.	2.9	34
52	PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. <i>Oncology Letters</i> , 2019, 18, 3471-3480.	1.8	10
53	High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Dereglated Activation of an ANRIL-ARF Bidirectional Promoter. <i>Non-coding RNA</i> , 2019, 5, 44.	2.6	21
54	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2019, 8, e1581556.	4.6	68

#	ARTICLE	IF	CITATIONS
55	A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1902-1912.	5.1	37
56	Cortical branched actin determines cell cycle progression. <i>Cell Research</i> , 2019, 29, 432-445.	12.0	64
57	Interaction between IGF2-PI3K axis and cancer-associated fibroblasts promotes anal squamous carcinogenesis. <i>International Journal of Cancer</i> , 2019, 145, 1852-1859.	5.1	13
58	Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas. <i>Cancers</i> , 2019, 11, 1846.	3.7	19
59	High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of <i>GPR126</i> in Bladder Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 469-475.	3.4	18
60	Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2109-2115.	7.0	65
61	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2605-2615.	7.0	45
62	Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1319-E1328.	7.1	27
63	Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers. <i>Breast Cancer Research</i> , 2018, 20, 28.	5.0	35
64	Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie. <i>ESMO Open</i> , 2018, 3, e000339.	4.5	37
65	Revisited analysis of a SHIVA 01 trial cohort using functional mutational analyses successfully predicted treatment outcome. <i>Molecular Oncology</i> , 2018, 12, 594-601.	4.6	3
66	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. <i>Modern Pathology</i> , 2018, 31, 68-82.	5.5	58
67	Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness. <i>Acta Neuropathologica</i> , 2018, 135, 267-283.	7.7	19
68	Tumor <i>PIK3CA</i> Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 981-990.	1.6	95
69	Distinct expression profiles and functions of Kindlins in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 281.	8.6	14
70	VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX. <i>BMC Biology</i> , 2018, 16, 109.	3.8	26
71	High rate of <i>PIK3CA</i> mutations but no <i>TP53</i> mutations in low-grade adenosquamous carcinoma of the breast. <i>Histopathology</i> , 2018, 73, 273-283.	2.9	33
72	Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences. <i>Cancer Medicine</i> , 2018, 7, 3213-3225.	2.8	13

#	ARTICLE	IF	CITATIONS
73	The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes. <i>EMBO Journal</i> , 2018, 37, .	7.8	22
74	Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function. <i>Oncogene</i> , 2018, 37, 6425-6441.	5.9	36
75	ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis. <i>Breast Cancer Research</i> , 2018, 20, 73.	5.0	56
76	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5767-5771.	7.0	68
77	MT1-MMP targeting to endolysosomes is mediated by flotillin upregulation. <i>Journal of Cell Science</i> , 2018, 131, .	2.0	29
78	Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 88.	5.0	53
79	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. <i>American Journal of Pathology</i> , 2018, 188, 2378-2391.	3.8	12
80	The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers. <i>Journal of Pathology</i> , 2018, 246, 103-114.	4.5	47
81	High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. <i>PLoS ONE</i> , 2018, 13, e0190619.	2.5	69
82	Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 464-476.	1.8	23
83	Involvement of the FOXO6 transcriptional factor in breast carcinogenesis. <i>Oncotarget</i> , 2018, 9, 7464-7475.	1.8	12
84	PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer. <i>Oncotarget</i> , 2018, 9, 23208-23219.	1.8	14
85	Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition. <i>Oncotarget</i> , 2018, 9, 29587-29600.	1.8	18
86	COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients. <i>Anticancer Research</i> , 2018, 38, 1485-1490.	1.1	9
87	First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. <i>Anticancer Research</i> , 2018, 38, 2909-2914.	1.1	3
88	Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration. <i>Journal of Cell Science</i> , 2017, 130, 938-949.	2.0	57
89	The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone. <i>Journal of Pathology</i> , 2017, 242, 73-89.	4.5	42
90	Baseline β -catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. <i>European Journal of Cancer</i> , 2017, 78, 70-81.	2.8	42

#	ARTICLE	IF	CITATIONS
91	Clinical value of R-spondins in triple-negative and metaplastic breast cancers. <i>British Journal of Cancer</i> , 2017, 116, 1595-1603.	6.4	31
92	Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts. <i>Journal of Proteome Research</i> , 2017, 16, 1868-1879.	3.7	17
93	Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 257-263.	1.6	29
94	Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26365.	1.5	56
95	Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. <i>British Journal of Cancer</i> , 2017, 117, 1819-1827.	6.4	15
96	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. <i>Oncotimmunology</i> , 2017, 6, e1358330.	4.6	15
97	Tubulin glycylation controls primary cilia length. <i>Journal of Cell Biology</i> , 2017, 216, 2701-2713.	5.2	67
98	Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2292-2303.	4.1	14
99	Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2116-2126.	7.0	28
100	The SHIVA01 trial: what have we learned?. <i>Pharmacogenomics</i> , 2017, 18, 831-834.	1.3	4
101	Neuronal Cholesterol Accumulation Induced by Cyp46a1 Down-Regulation in Mouse Hippocampus Disrupts Brain Lipid Homeostasis. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 211.	2.9	25
102	HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report. <i>International Journal of Cancer</i> , 2017, 141, 1667-1670.	5.1	29
103	Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts. , 2016, 57, 4916.		10
104	Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes. <i>Cancer Microenvironment</i> , 2016, 9, 107-118.	3.1	17
105	Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. <i>International Journal of Cancer</i> , 2016, 138, 2510-2521.	5.1	32
106	Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 1395-1404.	6.4	75
107	Expression of <i>ANRIL</i> "Polycomb Complexes" <i>CDKN2A/B/ARF</i> Genes in Breast Tumors: Identification of a Two-Gene (<i>EZH2/CBX7</i>) Signature with Independent Prognostic Value. <i>Molecular Cancer Research</i> , 2016, 14, 623-633.	3.4	84
108	Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. <i>Blood</i> , 2016, 127, 2231-2240.	1.4	54

#	ARTICLE	IF	CITATIONS
109	Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4449-4460.	3.6	10
110	MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. <i>Scientific Reports</i> , 2016, 6, 34935.	3.3	41
111	Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection. <i>British Journal of Cancer</i> , 2016, 114, 1387-1394.	6.4	43
112	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	6.3	71
113	CAG repeat size in Huntingtin alleles is associated with cancer prognosis. <i>European Journal of Human Genetics</i> , 2016, 24, 1310-1315.	2.8	19
114	Arpin downregulation in breast cancer is associated with poor prognosis. <i>British Journal of Cancer</i> , 2016, 114, 545-553.	6.4	25
115	Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 177-187.	6.4	67
116	p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. <i>Oncogene</i> , 2016, 35, 344-357.	5.9	76
117	Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial. , 2016, , .		10
118	PI3KCA mutation as an independent pronostic factor in anal squamous cell carcinoma treated by abdomino-perineal resection: Evidence from a retrospective cohort of 148 patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15060-e15060.	1.6	1
119	Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas. <i>Oncotarget</i> , 2016, 7, 47418-47430.	1.8	13
120	Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 48206-48219.	1.8	32
121	<i>ERBB2</i> mutations associated with solid variant of high-grade invasive lobular breast carcinomas. <i>Oncotarget</i> , 2016, 7, 73337-73346.	1.8	34
122	<i>MED12</i> mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways. <i>Oncotarget</i> , 2016, 7, 84428-84438.	1.8	27
123	Combination of COX-2 expression and <i>PIK3CA</i> mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. <i>Oncotarget</i> , 2016, 7, 85124-85141.	1.8	13
124	Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. <i>Oncotarget</i> , 2016, 7, 38467-38486.	1.8	31
125	mRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4523-4523.	1.6	0
126	Monitoring anti-PD-1 therapy efficacy by circulating tumor DNA: a prospective cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11535-11535.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSÃ© Program.. Journal of Clinical Oncology, 2016, 34, TPS11620-TPS11620.	1.6	1
128	Abstract 1524: Mutations and gene copy number variations landscape of metastases of various cancer types from patients enrolled in the SHIVA trial. , 2016, , .		1
129	The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clinical Epigenetics, 2015, 7, 57.	4.1	75
130	IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. PLoS ONE, 2015, 10, e0121395.	2.5	8
131	Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets. BioMed Research International, 2015, 2015, 1-14.	1.9	122
132	ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. British Journal of Cancer, 2015, 112, 1059-1066.	6.4	45
133	MiR-190b, the highest up-regulated miRNA in ER \pm -positive compared to ER \pm -negative breast tumors, a new biomarker in breast cancers?. BMC Cancer, 2015, 15, 499.	2.6	48
134	The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β -Catenin Coactivator BCL9-2 in Breast Cancer Cells. Molecular Cancer Research, 2015, 13, 902-912.	3.4	18
135	Precision medicine: lessons learned from the SHIVA trial â€œ Authors' reply. Lancet Oncology, The, 2015, 16, e581-e582.	10.7	13
136	Circulating tumor DNA as a nonâ€invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Molecular Oncology, 2015, 9, 783-790.	4.6	248
137	Alternative splicingâ€regulated protein of hepatitis B virus hacks the TNFâ€stimulated signaling pathways and limits the extent of liver inflammation. FASEB Journal, 2015, 29, 1879-1889.	0.5	18
138	Evaluating Patient-Derived Colorectal Cancer Xenografts as Preclinical Models by Comparison with Patient Clinical Data. Cancer Research, 2015, 75, 1560-1566.	0.9	117
139	Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients. Cell Cycle, 2015, 14, 3066-3078.	2.6	24
140	MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics. British Journal of Cancer, 2015, 113, 773-785.	6.4	12
141	Midkine Lacking Its Last 40 Amino Acids Acts on Endothelial and Neuroblastoma Tumor Cells and Inhibits Tumor Development. Molecular Cancer Therapeutics, 2015, 14, 213-224.	4.1	4
142	CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimerâ€™s disease. Brain, 2015, 138, 2383-2398.	7.6	163
143	Thrombin receptor PAR-1 activation on endothelial progenitor cells enhances chemotaxis-associated genes expression and leukocyte recruitment by a COX-2-dependent mechanism. Angiogenesis, 2015, 18, 347-359.	7.2	24
144	Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. Human Gene Therapy Clinical Development, 2015, 26, 113-124.	3.1	68

#	ARTICLE	IF	CITATIONS
145	<i>PIK3CA</i> Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2530-2537.	7.0	48
146	High-throughput pharmacogenetics identifies <i>SLCO1A2</i> polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 383-389.	2.5	11
147	<i>MAP3K8/TPL-2/COT</i> is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. <i>Nature Communications</i> , 2015, 6, 8583.	12.8	42
148	Unraveling the Role of Huntingtin in Breast Cancer Metastasis. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv208.	6.3	32
149	Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. <i>Human Molecular Genetics</i> , 2015, 24, 5965-5976.	2.9	96
150	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1324-1334.	10.7	897
151	SWI/SNF Chromatin Remodeling and Human Malignancies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 145-171.	22.4	242
152	Abstract 1687: Vandetanib as a potential new treatment for ER negative breast cancers. <i>Cancer Research</i> , 2015, 75, 1687-1687.	0.9	4
153	Tumor <i>PIK3CA</i> genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 516-516.	1.6	5
154	IL-1 β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. <i>Oncotarget</i> , 2015, 6, 29034-29047.	1.8	56
155	Abstract P2-05-06: Identification of specific gene signatures and alternative splice variants using exon array in Inflammatory breast Cancer. , 2015, , .		0
156	Assessment of functional impact of germline <i>BRCA1/2</i> variants located in noncoding regions in families with breast-ovarian cancer predisposition.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1542-1542.	1.6	0
157	Abstract 2400: Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for targeted sequencing in a prospective randomized trial for personalized treatment in all tumor type: The SHIVA study. , 2015, , .		0
158	Design and statistical principles of the SHIVA trial. <i>Chinese Clinical Oncology</i> , 2015, 4, 32.	1.2	1
159	Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts. <i>PLoS ONE</i> , 2014, 9, e104227.	2.5	10
160	Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1002-1013.	3.4	30
161	Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. <i>Nature Communications</i> , 2014, 5, 5005.	12.8	114
162	Reduction of MicroRNA 122 Expression in <i>IFNL3</i> CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. <i>Journal of Virology</i> , 2014, 88, 6394-6402.	3.4	29

#	ARTICLE	IF	CITATIONS
163	Protein kinase D1 regulates ER ⁺ positive breast cancer cell growth response to 17 β -estradiol and contributes to poor prognosis in patients. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 2536-2552.	3.6	23
164	Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. <i>Autophagy</i> , 2014, 10, 2122-2142.	9.1	130
165	TPD52 represents a survival factor in ERBB2 amplified breast cancer cells. <i>Molecular Carcinogenesis</i> , 2014, 53, 807-819.	2.7	31
166	α 6-Integrin Is Required for the Adhesion and Vasculogenic Potential of Hemangioma Stem Cells. <i>Stem Cells</i> , 2014, 32, 684-693.	3.2	21
167	Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. <i>BMC Cancer</i> , 2014, 14, 178.	2.6	21
168	The cytosolic carboxypeptidases CCP2 and CCP3 catalyze posttranslational removal of acidic amino acids. <i>Molecular Biology of the Cell</i> , 2014, 25, 3017-3027.	2.1	62
169	Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential. <i>Angiogenesis</i> , 2014, 17, 603-616.	7.2	14
170	Control of MT1-MMP transport by atypical PKC during breast-cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1872-9.	7.1	76
171	Tubulin glycolases are required for primary cilia, control of cell proliferation and tumor development in colon. <i>EMBO Journal</i> , 2014, 33, 2247-2260.	7.8	82
172	Tubulin glycolases are required for primary cilia, control of cell proliferation and tumor development in colon. <i>EMBO Journal</i> , 2014, 33, 2735-2735.	7.8	5
173	The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis. <i>Clinical Cancer Research</i> , 2014, 20, 358-371.	7.0	44
174	OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. <i>European Journal of Cancer</i> , 2014, 50, 2463-2477.	2.8	98
175	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting: IFCT/ERMETIC2 Project Part 1. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 45-55.	2.8	31
176	Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 4314-4325.	7.0	48
177	A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers. <i>Molecular Oncology</i> , 2014, 8, 1441-1457.	4.6	32
178	Predictor: Randomized phase II study of preoperative afatinib in untreated nonmetastatic head and neck squamous cell carcinoma patients (HNSCC) aiming at identifying predictive and pharmacodynamic biomarkers of efficacy. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS6105-TPS6105.	1.6	0
179	Abstract LB-30: Membrane-anchored MT1-MMP downstream of p63 is essential for the transition of in situ to invasive breast carcinoma. , 2014, , .		0
180	Abstract 4499: Activation of PI3-kinase pathway and tumor response to everolimus in patient-derived xenografts of triple-negative breast cancer. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
181	Abstract 1732: Biomarker-driven inhibition of MET and EGFR pathways in hepatocellular and cholangiocarcinoma models with increased efficacy in a sorafenib-tolerant model. , 2014, , .		0
182	MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics, 2013, 14, 473.	2.8	46
183	Identification of PHRF1 as a Tumor Suppressor that Promotes the TGF- β 2 Cytostatic Program through Selective Release of TGIF-Driven PML Inactivation. Cell Reports, 2013, 4, 530-541.	6.4	27
184	Inhibitory signalling to the Arp2/3 complex steers cell migration. Nature, 2013, 503, 281-284.	27.8	208
185	SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer, 2013, 13, 351.	2.6	52
186	microRNA expression profile in a large series of bladder tumors: Identification of a 3â€miRNA signature associated with aggressiveness of muscleâ€invasive bladder cancer. International Journal of Cancer, 2013, 132, 2479-2491.	5.1	152
187	Cell death and neuronal differentiation of glioblastoma stemâ€like cells induced by neurogenic transcription factors. Glia, 2013, 61, 225-239.	4.9	57
188	Variations in the mRNA expression of <i>poly(ADPâ€ribose) polymerases</i>, <i>poly(ADPâ€ribose) glycohydrolase</i> and <i>ADPâ€ribosylhydrolase 3</i> in breast tumors and impact on clinical outcome. International Journal of Cancer, 2013, 133, 2791-2800.	5.1	28
189	miRNA expression profiling of inflammatory breast cancer identifies a 5â€miRNA signature predictive of breast tumor aggressiveness. International Journal of Cancer, 2013, 133, 1614-1623.	5.1	67
190	Rare overexpression of anaplastic lymphoma kinase gene in inflammatory and non-inflammatory breast cancer. European Journal of Cancer, 2013, 49, 2774-2776.	2.8	4
191	In utero and lactational exposure to vinclozolin and genistein induces genomic changes in the rat mammary gland. Journal of Endocrinology, 2013, 216, 245-263.	2.6	20
192	A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. British Journal of Cancer, 2013, 108, 1720-1731.	6.4	46
193	PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer, 2013, 13, 545.	2.6	96
194	Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound. Marine Drugs, 2013, 11, 944-959.	4.6	37
195	A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas. PLoS ONE, 2013, 8, e66574.	2.5	7
196	Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments .. , 2013, , .		0
197	Abstract LB-34: Similar PI3K and RTK-Ras status in patient derived colorectal cancer-xenografts and patients.. , 2013, , .		0
198	Abstract LB-171: Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
199	Abstract A9: Establishment and characterization of residual breast cancer patient-derived xenografts resistant to neo-adjuvant therapy.. , 2013, , .		0
200	Abstract C174: Establishment of luminal breast cancer patient-derived xenografts with acquired resistance to both hormone therapy and everolimus.. , 2013, , .		0
201	Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. <i>Clinical Cancer Research</i> , 2012, 18, 2838-2849.	7.0	61
202	ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelialâ€Mesenchymal Transition and Invasion. <i>Cancer Research</i> , 2012, 72, 3593-3606.	0.9	107
203	Hedgehog pathway activation in human transitional cell carcinoma of the bladder. <i>British Journal of Cancer</i> , 2012, 106, 1177-1186.	6.4	50
204	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2736-2741.	7.1	95
205	Correction of Brain Oligodendrocytes by AAVrh.10 Intracerebral Gene Therapy in Metachromatic Leukodystrophy Mice. <i>Human Gene Therapy</i> , 2012, 23, 903-914.	2.7	73
206	Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2693-2703.	4.1	39
207	Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer. <i>Genes and Cancer</i> , 2012, 3, 63-70.	1.9	28
208	Correction: Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer Identifies Novel Genes Associated with Tumorigenicity. <i>Cancer Research</i> , 2012, 72, 3115-3115.	0.9	0
209	Increased secretion of Gas6 by smooth muscle cells in human atherosclerotic carotid plaques. <i>Thrombosis and Haemostasis</i> , 2012, 107, 140-149.	3.4	30
210	PIK3CA mutation impact on survival in breast cancer patients and in ER ⁺ , PR and ERBB2-based subgroups. <i>Breast Cancer Research</i> , 2012, 14, R28.	5.0	151
211	Malignant Germ Cellâ€Like Tumors, Expressing Ki-1 Antigen (CD30), Are Revealed during in Vivo Differentiation of Partially Reprogrammed Human-Induced Pluripotent Stem Cells. <i>American Journal of Pathology</i> , 2012, 180, 2084-2096.	3.8	24
212	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 527-532.	3.7	165
213	Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: A candidate biomarker to predict EGFR inhibitor effectiveness. <i>International Journal of Cancer</i> , 2012, 131, 1009-1010.	5.1	18
214	Quantification of <i>PKC</i> family genes in sporadic breast cancer by qRTâ€PCR: Evidence that <i>PKCδ</i> overexpression is an independent prognostic factor. <i>International Journal of Cancer</i> , 2012, 131, 2852-2862.	5.1	29
215	Comments on the use of a single or multiple probe set approach for microarray-based analyses of routine molecular markers in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 443-448.	2.5	3
216	Abstract B67: Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models. <i>Clinical Cancer Research</i> , 2012, 18, B67-B67.	7.0	0

#	ARTICLE	IF	CITATIONS
217	<i>ANRIL</i> , a long, noncoding RNA, is an unexpected major hotspot in GWAS. <i>FASEB Journal</i> , 2011, 25, 444-448.	0.5	413
218	Genome-Wide DNA Methylation Profiling of CpG Islands in Breast Cancer Identifies Novel Genes Associated with Tumorigenicity. <i>Cancer Research</i> , 2011, 71, 2988-2999.	0.9	141
219	Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. <i>Molecular Cancer</i> , 2011, 10, 23.	19.2	54
220	Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. <i>American Journal of Pathology</i> , 2011, 178, 2708-2715.	3.8	58
221	SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog. <i>Human Pathology</i> , 2011, 42, 434-443.	2.0	10
222	Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 54, 1073-1078.	3.7	50
223	Identification of Genes Potentially Involved in the Increased Risk of Malignancy in NF1-Microdeleted Patients. <i>Molecular Medicine</i> , 2011, 17, 79-87.	4.4	46
224	Similar NF- κ B Gene Signatures in TNF- α Treated Human Endothelial Cells and Breast Tumor Biopsies. <i>PLoS ONE</i> , 2011, 6, e21589.	2.5	37
225	Genome-based and transcriptome-based molecular classification of breast cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 93-99.	2.4	16
226	Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in) <i>Tj ETQq0 0 0 rgBT /Overlok 10 Tf 5</i>		
227	Isolation of mineralizing Nestin+ Nkx6.1+ vascular muscular cells from the adult human spinal cord. <i>BMC Neuroscience</i> , 2011, 12, 99.	1.9	9
228	An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predisposition. <i>BMC Medical Genetics</i> , 2011, 12, 121.	2.1	24
229	DNA methylation imprinting marks and DNA methyltransferase expression in human spermatogenic cell stages. <i>Epigenetics</i> , 2011, 6, 1354-1361.	2.7	118
230	Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions. <i>Cell Adhesion and Migration</i> , 2011, 5, 332-343.	2.7	27
231	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1713-1722.	6.3	106
232	Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1709-1719.	4.1	67
233	Thrombospondin-1 Is a Plasmatic Marker of Peripheral Arterial Disease That Modulates Endothelial Progenitor Cell Angiogenic Properties. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 551-559.	2.4	111
234	Role of the Focal Adhesion Protein Kindlin-1 in Breast Cancer Growth and Lung Metastasis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1323-1337.	6.3	69

#	ARTICLE	IF	CITATIONS
235	Clinical Relevance of Tumor Cells with Stem-Like Properties in Pediatric Brain Tumors. PLoS ONE, 2011, 6, e16375.	2.5	57
236	Abstract 3567: Interaction of pralatrexate with the EGFR/MAPK pathway leads to synergistic activity with EGFR inhibitors. , 2011, , .		0
237	Abstract 4264: CXCL12-CXCR4 axis in sunitinib-sensitive and -resistant hepatocarcinoma cells. , 2011, , .		0
238	Abstract 4531: Molecular determinants of sensitivity to pralatrexate in a panel of human cancer cell lines. , 2011, , .		0
239	Abstract 685: PTX-008 antiproliferative effects in cancer cells are mediated through galectin-1 inhibition and MAPK-dependent G2/M cell cycle arrest. , 2011, , .		0
240	Differential Distribution of erbB Receptors in Human Glioblastoma Multiforme: Expression of erbB3 in CD133-Positive Putative Cancer Stem Cells. Journal of Neuropathology and Experimental Neurology, 2010, 69, 606-622.	1.7	36
241	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood, 2010, 116, 4523-4531.	1.4	126
242	DNA Repair Gene Expression and Risk of Locoregional Relapse in Breast Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2010, 78, 328-336.	0.8	30
243	CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer, 2010, 10, 66.	2.6	87
244	A missense variant within BRCA1 exon 23 causing exon skipping. Cancer Genetics and Cytogenetics, 2010, 202, 144-146.	1.0	13
245	NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Human Mutation, 2010, 31, E1506-E1518.	2.5	208
246	Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. International Journal of Cancer, 2010, 126, 545-562.	5.1	110
247	<i>In vivo</i> hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. Journal of Pathology, 2010, 221, 264-274.	4.5	109
248	Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver International, 2010, 30, 1259-1269.	3.9	139
249	Gene Expression Profiling of the Hedgehog Signaling Pathway in Human Meningiomas. Molecular Medicine, 2010, 16, 262-270.	4.4	75
250	The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2544-2552.	2.4	60
251	Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase C β Inhibitor Enzastaurin in Colon Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 1308-1317.	4.1	34
252	Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Human Molecular Genetics, 2010, 19, 147-158.	2.9	67

#	ARTICLE	IF	CITATIONS
253	Differential Expression of <i>CCN1</i> , <i>CYR61</i> , <i>CCN3/NOV</i> , <i>CCN4/WISP1</i> , and <i>CCN5/WISP2</i> in Neurofibromatosis Type 1 Tumorigenesis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 60-69.	1.7	16
254	Identification of 5 novel genes methylated in breast and other epithelial cancers. <i>Molecular Cancer</i> , 2010, 9, 51.	19.2	83
255	Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway. <i>PLoS ONE</i> , 2010, 5, e15647.	2.5	56
256	Abstract 178: RASSF10 is frequently methylated in epithelial cancers. , 2010, , .		0
257	Abstract 165: MIRA (methylated CpG island recovery assay) assay identifies frequently methylated genes in breast cancer. , 2010, , .		0
258	Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. <i>Journal of Molecular Endocrinology</i> , 2009, 42, 87-103.	2.5	65
259	<i>Aspergillus fumigatus</i> germ tube growth and not conidia ingestion induces expression of inflammatory mediator genes in the human lung epithelial cell line A549. <i>Journal of Medical Microbiology</i> , 2009, 58, 174-179.	1.8	70
260	Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1528-1538.	3.3	148
261	Gene Expression Profiling of ErbB Receptors and Ligands in Human Meningiomas. <i>Cancer Investigation</i> , 2009, 27, 691-698.	1.3	20
262	Candidate Genes on Chromosome 9q33-34 Involved in the Progression of Childhood Ependymomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 1884-1892.	1.6	89
263	Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells. <i>Cancer Research</i> , 2009, 69, 4260-4269.	0.9	49
264	Interleukin 8 is differently expressed and modulated by PAR-1 activation in early and late endothelial progenitor cells. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2534-2546.	3.6	26
265	Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker. <i>European Urology</i> , 2009, 56, 678-689.	1.9	45
266	Quantitative PCR high-resolution melting (qPCR-HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: application to <i>MLH1</i> germline mutations in Lynch syndrome. <i>Human Mutation</i> , 2009, 30, 867-875.	2.5	58
267	Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 524-529.	2.8	31
268	Abstract B166: Effects of PTX-008, a non-peptidic topomimetic targeting galectin-1 in human epithelial cancer cells. , 2009, , .		1
269	Abstract B151: Epithelial-to-mesenchymal transition (EMT) in resistance to the antiproliferative effects of elisidepsin (Irvalec, C), a novel marine-derived depsipeptide, in colon cancer cells. , 2009, , .		0
270	Abstract C100: Evaluation of pyriplatin, a monofunctional cationic platinum(II) compound, in human cancer cells. , 2009, , .		0

#	ARTICLE	IF	CITATIONS
271	Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 305-313.	2.3	97
272	Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient. <i>European Journal of Human Genetics</i> , 2008, 16, 1459-1466.	2.8	30
273	mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene expression levels. <i>Cancer Science</i> , 2008, 99, 1992-2003.	3.9	66
274	NF-kappa B genes have a major role in Inflammatory Breast Cancer. <i>BMC Cancer</i> , 2008, 8, 41.	2.6	155
275	Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 975-986.	3.6	47
276	Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. <i>Molecular Cancer</i> , 2008, 7, 41.	19.2	145
277	A candidate molecular signature associated with tamoxifen failure in primary breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R88.	5.0	54
278	A Six-Gene Signature Predicting Breast Cancer Lung Metastasis. <i>Cancer Research</i> , 2008, 68, 6092-6099.	0.9	131
279	Gene Expression Study of Aurora-A Reveals Implication During Bladder Carcinogenesis and Increasing Values in Invasive Urothelial Cancer. <i>Urology</i> , 2008, 72, 873-877.	1.0	26
280	ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells. <i>Endocrine-Related Cancer</i> , 2008, 15, 125-138.	3.1	30
281	Overexpression of Vascular Endothelial Growth Factor 189 in Breast Cancer Cells Leads to Delayed Tumor Uptake with Dilated Intratumoral Vessels. <i>American Journal of Pathology</i> , 2008, 172, 167-178.	3.8	53
282	Significant gene expression differences in histologically Normal liver biopsies: Implications for control tissue. <i>Hepatology</i> , 2008, 48, 953-962.	7.3	25
283	MRNA EXPRESSION LEVELS AND PROGNOSTIC VALUE OF 40 ANGIOGENIC GENES IN A LARGE SERIES OF 157 BLADDER TUMORS. <i>Journal of Urology</i> , 2008, 179, 266-266.	0.4	0
284	HEDGEHOG PATHWAY INVOLVEMENT IN BLADDER CARCINOGENESIS: A STUDY OF 71 PATIENTS. <i>Journal of Urology</i> , 2008, 179, 318-319.	0.4	1
285	Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells. <i>Molecular and Cellular Biology</i> , 2008, 28, 1114-1123.	2.3	80
286	Association Analysis Indicates That a Variant GATA-Binding Site in the PIK3CB Promoter Is a Cis-Acting Expression Quantitative Trait Locus for This Gene and Attenuates Insulin Resistance in Obese Children. <i>Diabetes</i> , 2008, 57, 494-502.	0.6	21
287	Nonredundant Functions for Tumor Protein D52-Like Proteins Support Specific Targeting of TPD52. <i>Clinical Cancer Research</i> , 2008, 14, 5050-5060.	7.0	50
288	16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2817-2827.	4.1	17

#	ARTICLE	IF	CITATIONS
289	Ex Vivo Priming of Endothelial Progenitor Cells With SDF-1 Before Transplantation Could Increase Their Proangiogenic Potential. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 644-650.	2.4	174
290	Bone Morphogenetic Proteins 2 and 4 Are Selectively Expressed by Late Outgrowth Endothelial Progenitor Cells and Promote Neoangiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 2137-2143.	2.4	101
291	Oligonucleotide microarray analysis of estrogen receptor β -positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. <i>Journal of Molecular Endocrinology</i> , 2007, 39, 305-318.	2.5	26
292	Genetics, Genomics, and Proteomics: Implications for the Diagnosis and the Treatment of Chronic Hepatitis C. <i>Seminars in Liver Disease</i> , 2007, 27, 013-027.	3.6	55
293	High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors. <i>Endocrine-Related Cancer</i> , 2007, 14, 691-702.	3.1	54
294	CXC chemokines located in the 4q21 region are up-regulated in breast cancer. <i>Endocrine-Related Cancer</i> , 2007, 14, 1039-1052.	3.1	145
295	Microarray-Based Identification of Tenascin C and Tenascin XB, Genes Possibly Involved in Tumorigenesis Associated with Neurofibromatosis Type 1. <i>Clinical Cancer Research</i> , 2007, 13, 398-407.	7.0	48
296	Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 731-742.	1.5	300
297	Novel Mouse Model of Monocular Amaurosis Fugax. <i>Stroke</i> , 2007, 38, 3237-3244.	2.0	23
298	p63 Gene Expression Study and Early Bladder Carcinogenesis. <i>Urology</i> , 2007, 70, 459-462.	1.0	17
299	In vivo altered unfolded protein response and apoptosis in livers from lipopolysaccharide-challenged cirrhotic rats. <i>Journal of Hepatology</i> , 2007, 46, 1075-1088.	3.7	62
300	Characterization of a Germ-Line Deletion, Including the Entire <i>INK4/ARF</i> Locus, in a Melanoma-Neural System Tumor Family: Identification of <i>ANRIL</i> , an Antisense Noncoding RNA Whose Expression Coclusters with <i>ARF</i> . <i>Cancer Research</i> , 2007, 67, 3963-3969.	0.9	582
301	Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2007, 56, 1315-1324.	6.7	28
302	Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances <i>in vitro</i> angiogenesis with up-regulation of integrin β_6 . <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1149-1161.	3.6	85
303	773: Loss of Expression of Candidate Tumor Suppressor Gene ATIP/MTUS1 in Human Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2007, 177, 259-259.	0.4	0
304	Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. <i>Neoplasia</i> , 2006, 8, 312-318.	5.3	36
305	Gene Expression Profiling of ERBB Receptors and Ligands in Human Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 175, 1127-1132.	0.4	38
306	Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. <i>Gene</i> , 2006, 380, 127-136.	2.2	82

#	ARTICLE	IF	CITATIONS
307	Role of estrogen receptor $\hat{\pm}$ transcriptional coregulators in tamoxifen resistance in breast cancer. <i>Maturitas</i> , 2006, 54, 342-351.	2.4	54
308	Exploring the Distinctive Biological Characteristics of Pilocytic and Low-Grade Diffuse Astrocytomas Using Microarray Gene Expression Profiles. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 794-807.	1.7	46
309	Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis. <i>Critical Care Medicine</i> , 2006, 34, 219-222.	0.9	88
310	Identification of the first intragenic deletion of the PITX2 gene causing an Axenfeld-Rieger Syndrome: case report. <i>BMC Medical Genetics</i> , 2006, 7, 82.	2.1	14
311	Is Quantitative Real-Time RT-PCR an Adjunct to Immunohistochemistry for the Evaluation of ErbB2 Status in Transitional Carcinoma of the Bladder?. <i>European Urology</i> , 2006, 49, 1035-1043.	1.9	6
312	Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. <i>Endocrine-Related Cancer</i> , 2006, 13, 1109-1120.	3.1	208
313	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.. <i>Clinical Cancer Research</i> , 2006, 12, 1157-1167.	7.0	495
314	PAR-1 Activation on Human Late Endothelial Progenitor Cells Enhances Angiogenesis In Vitro With Upregulation of the SDF-1/CXCR4 System. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2321-2327.	2.4	119
315	Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. <i>Virology</i> , 2005, 332, 130-144.	2.4	145
316	Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2005, 52, 2917-2925.	6.7	76
317	Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. <i>Human Molecular Genetics</i> , 2005, 14, 1293-1303.	2.9	74
318	Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1-3 by quantitative RT-PCR. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1803-10.	3.3	25
319	Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2005, 129, 2064-2075.	1.3	161
320	Update on inflammatory breast cancer. <i>Breast Cancer Research</i> , 2005, 7, 52-8.	5.0	65
321	The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2004, 91, 248-254.	3.4	34
322	Molecular Profiling of Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6789-6795.	7.0	213
323	RASSF4/AD037 Is a Potential Ras Effector/Tumor Suppressor of the RASSF Family. <i>Cancer Research</i> , 2004, 64, 8688-8693.	0.9	108
324	Molecular Profiles of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , 2004, 10, 3763-3771.	7.0	34

#	ARTICLE	IF	CITATIONS
325	Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. <i>Oncogene</i> , 2004, 23, 2408-2419.	5.9	119
326	Evaluation of mRNA expression of estrogen receptor β and its isoforms in human normal and neoplastic endometrium. <i>International Journal of Cancer</i> , 2004, 110, 783-787.	5.1	30
327	MOLECULAR PROFILING OF BENIGN PROSTATIC HYPERPLASIA USING A LARGE SCALE REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION APPROACH. <i>Journal of Urology</i> , 2004, 172, 1382-1385.	0.4	14
328	Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. <i>Gastroenterology</i> , 2004, 126, 1323-1329.	1.3	205
329	Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. <i>Molecular Cancer</i> , 2004, 3, 20.	19.2	85
330	Identification of a three-gene expression signature of poor-prognosis breast carcinoma. <i>Molecular Cancer</i> , 2004, 3, 37.	19.2	30
331	Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. <i>Breast Cancer Research</i> , 2004, 6, R252-63.	5.0	89
332	Altered expression pattern of alternatively spliced estrogen receptor β transcripts in breast carcinoma. <i>Cancer Letters</i> , 2004, 215, 101-112.	7.2	31
333	Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family. <i>Human Mutation</i> , 2003, 21, 654-654.	2.5	24
334	Prognostic value of ERBBfamily mRNA expression in breast carcinomas. <i>International Journal of Cancer</i> , 2003, 106, 758-765.	5.1	184
335	Quantitative RT-PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis. <i>Journal of Pathology</i> , 2003, 201, 260-267.	4.5	32
336	A quantitative gene expression study suggests a role for angiotensin II in focal nodular hyperplasia. <i>Gastroenterology</i> , 2003, 124, 651-659.	1.3	101
337	Molecular Profiling of Hepatocellular Carcinomas (HCC) Using a Large-Scale Real-Time RT-PCR Approach. <i>American Journal of Pathology</i> , 2003, 163, 733-741.	3.8	90
338	Quantitative RT-PCR reveals a ubiquitous but preferentially neural expression of the KIS gene in rat and human. <i>Molecular Brain Research</i> , 2003, 114, 55-64.	2.3	24
339	Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP. <i>Genomics</i> , 2003, 81, 400-410.	2.9	51
340	Placenta-Specific INSL4 Expression Is Mediated by a Human Endogenous Retrovirus Element1. <i>Biology of Reproduction</i> , 2003, 68, 1422-1429.	2.7	86
341	Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. <i>Carcinogenesis</i> , 2003, 25, 405-411.	2.8	49
342	An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. <i>Blood</i> , 2003, 101, 1833-1840.	1.4	99

#	ARTICLE	IF	CITATIONS
343	Expression profiling in liver cirrhosis and hepatocellular carcinoma (HCC) using a large scale real time RT-PCR approach. <i>Journal of Hepatology</i> , 2002, 36, 73.	3.7	0
344	CGA Gene (Coding for the $\hat{1}\pm$ Subunit of Glycoprotein Hormones) Overexpression in ER $\hat{1}\pm$ -Positive Prostate Tumors. <i>European Urology</i> , 2002, 41, 335-341.	1.9	17
345	Evidence of chromosome regions and gene involvement in inflammatory breast cancer. <i>International Journal of Cancer</i> , 2002, 102, 618-622.	5.1	25
346	Genetic pathways in the evolution of breast ductal carcinoma in situ. <i>Journal of Pathology</i> , 2002, 196, 280-286.	4.5	68
347	Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. <i>Oncogene</i> , 2002, 21, 7593-7597.	5.9	78
348	Analyses of MYC, ERBB2, and CCND1 Genes in Benign and Malignant Thyroid Follicular Cell Tumors by Real-Time Polymerase Chain Reaction. <i>Thyroid</i> , 2001, 11, 147-152.	4.5	60
349	Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2001, 114, 281-289.	2.5	18
350	hTERT expression in sporadic renal cell carcinomas. <i>Journal of Pathology</i> , 2001, 195, 209-217.	4.5	21
351	The CGA gene as new predictor of the response to endocrine therapy in ER $\hat{1}\pm$ -positive postmenopausal breast cancer patients. <i>Oncogene</i> , 2001, 20, 6955-6959.	5.9	22
352	Quantification of estrogen receptor $\hat{1}\pm$ and $\hat{1}^2$ expression in sporadic breast cancer. <i>Oncogene</i> , 2001, 20, 8109-8115.	5.9	118
353	Human TIP49b/RUVBL2 gene: genomic structure, expression pattern, physical link to the human CGB/LHB gene cluster on chromosome 19q13.3. <i>Annales De G�n�tologie</i> , 2000, 43, 69-74.	0.4	15
354	Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. <i>Molecular Carcinogenesis</i> , 2000, 29, 151-158.	2.7	1
355	TaqMan PCR-based Gene Dosage Assay for Predictive Testing in Individuals from a Cancer Family with INK4 Locus Haploinsufficiency. <i>Clinical Chemistry</i> , 1999, 45, 982-986.	3.2	141
356	Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. , 1999, 24, 255-263.		49
357	Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study. <i>Genes Chromosomes and Cancer</i> , 1999, 25, 212-221.	2.8	34
358	Infrequent mutations of the MET gene in sporadic breast tumours. , 1999, 82, 908-910.		13
359	Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer. <i>Human Pathology</i> , 1999, 30, 809-815.	2.0	31
360	Low frequency of TSG101/CC2 gene alterations in invasive human breast cancers. <i>Oncogene</i> , 1998, 16, 677-679.	5.9	17

#	ARTICLE	IF	CITATIONS
361	Molecular analysis of the FHIT gene in human prostate cancer. <i>Oncogene</i> , 1998, 16, 1863-1868.	5.9	14
362	Novel approach to quantitative polymerase chain reaction using real-time detection: Application to the detection of gene amplification in breast cancer. <i>International Journal of Cancer</i> , 1998, 78, 661-666.	5.1	5
363	MUC1 Mucin Gene, Transcripts, and Protein in Adenomas and Papillary Carcinomas of the Thyroid. <i>Thyroid</i> , 1997, 7, 725-731.	4.5	41
364	A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. <i>Cancer Genetics and Cytogenetics</i> , 1997, 98, 75-80.	1.0	33
365	11q13 Amplification in local recurrence of human primary breast cancer. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 128-133.	2.8	37
366	Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 304-306.	2.8	27
367	Genetic alterations in breast cancer. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 227-251.	2.8	251
368	Brief communications oncogene amplification per se: An independent prognostic factor in human breast cancer. <i>Molecular Carcinogenesis</i> , 1994, 11, 189-191.	2.7	7
369	Loss of heterozygosity of the L-myc oncogene in human breast tumors. <i>Human Genetics</i> , 1990, 85, 101-5.	3.8	40